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Background: It has been suggested that antidepressant benefits are smaller for mild than severe
depression. Because antidepressants are also used for anxiety disorders, obsessive-compulsive
disorder (OCD), and posttraumatic stress disorder (PTSD), we examined the influence of severity
for these disorders.
Methods:We used individual patient data of eight trials (3,430 participants) for generalized anx-
iety disorder (GAD); four trials (1,195 participants) for social anxiety disorder (SAD); four trials
(1,132 participants) for OCD; three trials (1,071 participants) for PTSD; and 10 trials (2,151 par-
ticipants) for panic disorder (PD). Mixed-effects models were used to investigate an interaction
between severity and treatment group.
Results: For GAD and PD, severity moderated antidepressant efficacy. The antidepressant–
placebo difference was 1.4 (95% CI: 0.4–2.5; SMD: 0.21) Hamilton Anxiety Rating Scale (HAM-
A) points for participants with mild GAD (baseline HAM-A= 10), increasing to 4.0 (3.4–4.6; SMD:
0.45) or greater for severely ill participants (HAM-A≥30). For PD, the differencewas0.4 (0.3–0.6)
panic attacks/2 weeks for participants with 10 panic attacks/2 weeks at baseline, increasing to
4.7 (3.0–6.4) for participants with 40. For SAD, OCD, and PTSD, no interaction was found. Across
severity levels, the differences were 16.1 (12.9–19.3; SMD: 0.59) Liebowitz Social Anxiety Scale
points, 3.4 (2.5–4.4, SMD: 0.39) Yale–Brown Obsessive-Compulsive Scale points, and 10.3 (6.9–
13.6; SMD: 0.41) Clinician-Administered PTSD Scale points.
Conclusions:Antidepressants areequally effective across severity levels for SAD,OCD, andPTSD.
For GAD and PD, however, benefits are small at low severity, and the benefit–risk ratio may be
unfavorable for these patients.
K EYWORDS
antidepressive agents, anxiety disorders, meta-analysis, obsessive-compulsive disorder, panic dis-
order, posttraumatic stress disorder
1 INTRODUCTION
Antidepressants are considered effective treatments for major
depressive disorder (MDD) (Qaseem, Barry, & Kansagara, 2016), anx-
iety disorders (Bandelow et al., 2015), obsessive-compulsive disorder
(OCD) (Soomro, Altman, Rajagopal, & Oakley Browne, 2008), and
posttraumatic stress disorder (PTSD) (Stein, Ipser, & Seedat, 2006).
However, research inMDDhas suggested that antidepressant efficacy
may depend upon initial symptom severity. Both trial-level (Khan,
Leventhal, Khan, & Brown, 2002; Kirsch et al., 2008) and individual
patient data (IPD) meta-analyses (Fournier et al., 2010; Khan, Bhat,
Faucett, Kolts, & Brown, 2011; Khan, Brodhead, Kolts, & Brown,
2005) have found that antidepressants are more effective for patients
with high initial severity, with some of these analyses suggesting that
efficacy is minimal for patients with mild depression (Fournier et al.,
2010; Kirsch et al., 2008). Consequently, many guidelines no longer
recommend antidepressants for mild depression (National Institute
for Health and Care Excellence, 2009; Spijker et al., 2013). Recently,
however, two substantially larger IPD meta-analyses did not find an
association between severity and antidepressant efficacy for MDD
(Gibbons, Hur, Brown, Davis, & Mann, 2012; Rabinowitz et al., 2016),
indicating that this question is not yet settled.
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Antidepressants are also commonly used for anxiety disorders,
OCD, and PTSD (Wong et al., 2016), but comparatively little evidence
regarding the influence of severity is available for these disorders.
Trial-level meta-analyses have found no evidence that antidepressant
efficacy increases with increasing severity (Ackerman & Greenland,
2002; Curtiss, Andrews, Davis, Smits, & Hofmann, 2017; Davis, Smits,
& Hofmann, 2014; de Vries, de Jonge, van denHeuvel, Turner, & Roest,
2016; Sugarman, Loree, Baltes, Grekin, &Kirsch, 2014). However, such
trial-level analysesmay be prone to the ecological fallacy (Thompson&
Higgins, 2002), inwhicha trial-level relationship canbe found thatdoes
not exist at the participant level, or vice versa. They can also be under-
powered and suffer from a restriction of range. Hence, IPD is needed
to provide better insight intowhether initial severity is associatedwith
antidepressant efficacy for anxiety disorders.
However, few studies have used IPD and most of these studies had
significant limitations. Two studies examined efficacy in subgroups of
less and more severely anxious patients without actually testing for
differences (Pae et al., 2015; Stein, Kasper, Andersen, Nil, & Lader,
2004). Two other studies tested the association between GAD sever-
ity and dichotomized outcomes, with one analysis reporting a signif-
icant association only for remission (Montgomery, Sheehan, Meoni,
Haudiquet, & Hackett, 2002) and the other only for response (Pollack,
Meoni, Otto, Simon, & Hackett, 2003). Two patient-level analyses for
SAD found contradictory results, with one reporting greater efficacy in
more severely anxious participants than in less severely anxious par-
ticipants (Montgomery, 1998), while the other reported similar effi-
cacy (Stein, Stein, Goodwin, Kumar, &Hunter, 2001). Finally, a post hoc
analysis of a trial for PTSD found no evidence for moderation by initial
severity, but this was a negative trial, which may have made it impossi-
ble to detect suchmoderation. To our knowledge, there are no patient-
level analyses forOCDor PD.Given the limitations of the available evi-
dence (including dichotomization of outcomes and predictors, which
leads to a significant loss of power (Altman & Royston, 2006)) and the
conflicting results, the question of whether initial severity moderates
antidepressant efficacy for anxiety disorders, OCD, and PTSD remains
unanswered. In the current study,we therefore examined this question
using IPD from 29 trials enrolling 8,979 participants.
2 MATERIALS AND METHODS
2.1 Data source
We requested IPD from Clinical Study Data Request (CSDR,
https://clinicalstudydatarequest.com). We first identified all selective
serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine
reuptake inhibitors (SNRIs) developed by participating sponsors.
These were paroxetine (GlaxoSmithKline), fluoxetine (Lilly), and dulox-
etine (Lilly). Although other SSRIs and SNRIs are also used for anxiety
disorders, these were not available through CSDR. We then identified
all double-blind, placebo-controlled, and short-term (≤16 weeks) ran-
domized controlled trials (RCTs) of these antidepressants for an anxi-
ety disorder, OCD, or PTSD in adults that werementioned in Food and
DrugAdministration (FDA) drug approval packages (Roest et al., 2015)




Asour primary outcome,we chose the outcomeusually considered pri-
mary for that disorder. ForGAD, thiswas theHamiltonRating Scale for
Anxiety (HAM-A); for SAD, the Liebowitz Social Anxiety Scale (LSAS);
for OCD, the Yale–Brown Obsessive-Compulsive Scale (Y-BOCS); and
for PTSD, the Clinician-Administered PTSD Scale (CAPS). For PD,most
trials used response (defined as having 0 full panic attacks) as an out-
come, but we selected the number of full panic attacks per 2 weeks,
since dichotomization leads to a significant loss of information (Altman
& Royston, 2006).
2.3 Patient population
We included patients with a valid baseline score and at least one valid
follow-up score on the primary outcome (modified intention-to-treat
population). Patients assigned to placebo, the investigative antide-
pressant, or a comparator SSRI or SNRI were included. We excluded
patients assigned to other active comparators.
2.4 Statistical analysis
We conducted separate analyses for each disorder. For GAD, SAD,
OCD, and PTSD, we applied linear mixed models, using the nlme pack-
age (version 3.1-127) for R (3.3.0). The effect measure of interest was
the change from baseline on the primary outcome. The initial model
included all fixed effects, regardless of significance. These were initial
severity, treatment group, linear and quadratic terms for time (in days
since baseline), and their two- and three-way interactions. Baseline
and change scores were grand-mean centered and standardized,
while time was centered at trial endpoint and standardized. Using
this first model, we modeled the covariance structure of the nested
data. We considered random intercepts at trial and participant level
and random effects for linear and quadratic time. For these random
effects, we examined compound symmetry, diagonal and unstructured
covariance matrices, and autocorrelation terms for the residuals. We
used restricted maximum likelihood (REML) for estimation and the
Akaike InformationCriterion (AIC) to select the best-fitting covariance
structure.
Subsequently,we refitted themodel usingmaximum likelihood (ML)
and removed nonsignificant fixed effects by backward selection. If an
interaction or quadratic effect was significant, we retained all compo-
nent main or linear effects regardless of significance.We used the AIC
to select the best-fitting model. However, for clarity we further simpli-
fied models containing nonsignificant terms even if the more complex
model had a marginally lower AIC. In these cases, both the Bayesian
Information Criterion (BIC) and the likelihood ratio test also favored
the simpler models. A standardized mean difference (SMD) was calcu-
lated by dividing the drug-placebo difference in change scores by the
pooled standard deviation of the change score at endpoint (imputed
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where necessary and stratified by baseline severity in case of a signifi-
cant interaction between severity and treatment group).
For PD, we applied a negative binomial mixed model, using the
glmer.nb command from the lme4 package (version 1.1-12). The effect
measure of interestwas the number of panic attacks/2weeks. Because
this measure was highly skewed, we replaced values ≥100 (45 (0.4%)
of 11,785observations) by a newvalue between70 and100 (randomly
drawn fromauniformdistribution) to improvemodel convergence. The
initial model included the same fixed effects as for the other disor-
ders. For the covariance structure, we considered only random inter-
cepts at trial and participant level and a random effect for linear time,
as models including a random effect for quadratic time failed to con-
verge. Since lme4doesnot easily allow for either autocorrelationordif-
ferent covariance structures, we onlymodeled an unstructured covari-
ance matrix. We subsequently selected the best-fitting model using
backward selection of the fixed effects, as done for the other disor-
ders. Because of the nonnormal distribution of panic attacks, we did
not include a standardized difference for PD.
For all disorders, we also analyzed (prespecified) models that
included age and gender as covariates, which yielded similar results
and hence are not described further. We conducted several other post
hoc sensitivity analyses. First, we excluded dosages below the FDA-
approved dose range (e.g., 10 mg paroxetine for PD). Secondly, we
excluded participants with very low baseline scores, because some tri-
als included a small number of participants with even, in some cases,
scoreswithin the range generally thought to correspond to “absence of
illness” (although all participants met diagnostic criteria for the disor-
der under study). Finally, we analyzed an alternative outcome for PD,
the Panic Disorder Severity Scale (PDSS) (Shear et al., 1997), a more
comprehensive measure that was only available in two out of 10 PD
trials. For this analysis, we followed the approach also taken for GAD,
SAD, OCD, and PTSD.
3 RESULTS
3.1 Trials and participants
We identified 34 trials, but we excluded one trial of paroxetine for
PD (29060/108 (Oehrberg et al., 1995)) a priori, as it did not dis-
tinguish between full and limited-symptom panic attacks. We were
denied access to four other trials: electronic data was not available
for a trial of fluoxetine for OCD (E079 (Montgomery et al., 1993),
completed in 1991), while GlaxoSmithKline considered the translation
costs for three (unpublished) Japanese trials of paroxetine for GAD or
SAD (29060/661, 29060/856, and PIR104776) to be prohibitive. One
of these trials was positive (PIR104776), i.e., had statistically signifi-
cant results for the primary outcome, while the other three were neg-
ative.
We received access to 29 trials with 3,656 placebo-treated and
5,323antidepressant-treatedparticipants. Two trials (of duloxetine for
GAD) included an active comparator (venlafaxine extended release).
For GAD, we had access to eight trials (six positive) with 1,342
placebo-treated and 2,088 antidepressant-treated participants; for
SAD, four trials (all positive) with 514 placebo-treated and 681
antidepressant-treated participants; for OCD, four trials (three posi-
tive) with 350 placebo-treated and 782 antidepressant-treated partic-
ipants; for PTSD, three trials (two positive) with 459 placebo-treated
and 612 antidepressant-treated participants; and for PD, 10 trials (five
positive) with 991 placebo-treated and 1,160 antidepressant-treated
participants (see flow chart in Supporting Information Figure 1 for trial
selection, Table 1 for baseline characteristics, and Supporting Informa-
tion Tables 1 and 2 for individual trial information).
3.2 GAD, SAD, OCD, and PTSD
For all four disorders, a model with an unstructured covariance matrix
(including all random effects) and autocorrelated errors fit best. For
GAD, the best-fittingmodel included the two-way interaction between
baseline scoreand treatment group, butnot the three-way interactions
between baseline score, treatment group, and time (Figure 1a). For
SAD, OCD, and PTSD, the best-fitting model did not include any of the
interactions between baseline score and treatment group (Figure 1b–
d). Model specifications are provided in Supporting Information
Table 3. For all disorders, there was a significant main effect of base-
line score, resulting in a greater change from baseline with increasing
severity in both treatment groups, consistent with a regression to the
mean effect.
For GAD, the estimated benefit of antidepressants (compared to
placebo) at trial endpoint (8 weeks) was 1.4 (95% CI: 0.4–2.5, SMD:
0.21) points on the HAM-A for participants with a baseline score of
10, increasing to 4.0 (95% CI: 3.4–4.6, SMD: 0.45) for participants
with a baseline score of 30 (Table 2). Because there was no signifi-
cant relationship between initial severity and antidepressant efficacy
for SAD, OCD, and PTSD, the best-fitting model estimated the same
antidepressant–placebo difference across the severity range. For SAD,
it was 16.1 (95%CI: 12.9–19.3, SMD: 0.59) LSAS points atweek 12; for
OCD, 3.4 (95%CI: 2.5–4.4, SMD: 0.39) Y-BOCS points at week 12; and
for PTSD, 10.3 (95%CI: 6.9–13.6, SMD: 0.41) CAPS points at week 12.
3.3 Panic disorder
For PD, the model with the lowest AIC (38,267.2) contained the two-
way interaction between baseline severity and group, but because this
term was not significant (p = 0.11), we preferred a more parsimonious
model without the interaction and with an only marginally larger AIC
(38,268.6 after removing two nonsignificant terms, see Supporting
Information Table 3). This model indicated that the drug-placebo
difference was constant on the log scale of the negative binomial
model and hence that the ratio of the endpoint number of panic
attacks/2 weeks in the placebo group compared to the drug group
was constant (2.46) on the original scale. Consequently, the absolute
difference between drug and placebo groups actually increased with
increasing severity (Figure 2). For participants experiencing two panic
attacks/2 weeks at baseline, the estimated drug–placebo difference
was 0.2 (95% CI: 0.2–0.3) (in favor of antidepressants) at week 10.
This increased to 0.4 (95% CI: 0.3–0.6) for participants experienc-
ing 10 panic attacks/2 weeks at baseline, 0.9 (95% CI: 0.7–1.2) for
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TABLE 1 Baseline characteristics for each disorder
Gender (% Female) Mean Age (SD) Mean Baseline Score (SD) Baseline Range
GAD 62.3 42.0 (13.4) 25.1 (5.9) 2–50
SAD 46.8 37.3 (11.0) 80.2 (24.0) 7–139
OCD 44.4 38.7 (12.4) 25.0 (5.3) 10–40
PTSD 62.6 41.1 (11.7) 75.2 (16.6) 30–132
Gender (% Female) Mean Age (SD) Median Baseline Score (IQR) Baseline Range
Panic disorder 61.4 37.3 (10.5) 5 (3–11) 0–99
Notes. The baseline score is determined as the score at baseline on the Hamilton Anxiety Rating Scale (HAM-A) for GAD, the Liebowitz Social Anxiety Scale
(LSAS) for SAD, the Yale–Brown Obsessive-Compulsive Scale (Y-BOCS) for OCD, the Clinician-Administered PTSD Scale (CAPS) for PTSD, and the number
of panic attacks/2 weeks for panic disorder.
participants experiencing 20, and 4.7 (95%CI: 3.0–6.4) for participants
experiencing 40 (Table 3).
3.4 Post hoc analyses
The results of our post hoc analyses excluding unapproved dosages or
participants with very low baseline scores were similar to our main
analyses (Supporting Information Tables 4–6). In the post hoc analy-
sis of the PDSS for PD, the best-fitting model included both the two-
way interaction between baseline severity and treatment group and
the three-way interaction between severity, treatment group, and time
(Supporting Information Tables 7 and 8). At endpoint (week 12), the
antidepressant–placebo difference was 0.0 (95% CI: –1.9 to 2.0; SMD:
0.00) for participants with moderate illness (baseline PDSS of 12), 3.9
(95%CI: 2.7–5.2; SMD: 0.59) for participants with severe illness (base-
line PDSS of 18), and 5.9 (95% CI: 4.1–7.7; SMD: 1.00) for participants
with very severe illness (baseline PDSS of 21).
4 DISCUSSION
4.1 Principal findings
To our knowledge, this is the first individual patient datameta-analysis
examining the relationship between baseline severity and antide-
pressant efficacy for anxiety disorders, OCD, and PTSD. We showed
that initial severity moderates antidepressant efficacy for GAD, but
not for SAD, OCD, and PTSD. For PD, the ratio between the number
of panic attacks in the placebo group compared to the drug group
was constant, but the absolute antidepressant-placebo difference
was small for patients experiencing few panic attacks at baseline and
increased with increasing severity. For all disorders, a regression to
themean or law of initial value effect occurred, but this cannot explain
the interaction between baseline severity and treatment in GAD.
Our findings are partially in agreement with our earlier trial-level
meta-analysis, confirming that initial severity does not influence
antidepressant efficacy for SAD,OCD, and PTSD (deVries et al., 2016).
However, our finding that initial severity does affect antidepressant
efficacy for GAD and PD diverges from our earlier study, in which no
effect of initial severity was apparent for these disorders either. These
differences are likely because of the much larger sample size and the
use of IPD in this study, which allows for the detection of smaller
interaction effects. Furthermore, for PD we used a different outcome
in this study (number of panic attacks/2 weeks instead of remission).
The SMDs for SAD and PTSDwere also larger than those found earlier
(Roest et al., 2015). This is probably at least in part because the parox-
etine trials had higher effect sizes than trials of other drugs for these
disorders, which we were unable to include in this study. The larger
SMDsmay also be due, in part, to different analytical techniques, since
our previous meta-analysis used last-observation-carried-forward
(LOCF) to handle missing data, while the current study employed
mixedmodels.
It is unclear why we found a relationship between initial severity
and antidepressant efficacy for GAD and PD, but not for the other dis-
orders. GAD is often considered to be more closely related to MDD
than the other anxiety disorders (Krueger, 1999) and the HAM-A also
overlaps with the Hamilton Depression Rating Scale (HAM-D). On the
other hand, since the association between initial severity and antide-
pressant efficacy inMDD has been called into question (Gibbons et al.,
2012; Rabinowitz et al., 2016), a greater similarity between MDD
and GAD might not explain our findings. HAM-A items also tend to
be relatively nonspecific, covering common symptoms like insomnia,
tension, and worries, while the LSAS and Y-BOCS specifically exam-
ine distress associated with respectively social situations and obses-
sions/compulsions, and the CAPS examines both general distress and
specific trauma-related distress. Such general distress symptoms, par-
ticularly when mild, may be more responsive to placebo or more likely
to improve spontaneously. However, this would not explain the signifi-
cant relationship between severity and antidepressant efficacy for PD,
since both the number of panic attacks and the PDSS examine panic-
specific symptoms.
It is also important to note that we had the largest sample size for
GAD, although our sensitivity analyses for PD included relatively few
participants and also yielded a significant interaction effect. Since we
had more than 1,000 participants for each disorder, we should have
been able to detect a substantial interaction effect, but it is possible
that smaller interaction effects for the other disorders were missed.
However, these are less likely to be of clinical significance.
4.2 Strengths and limitations
The main strength of this study is that we used IPD and had a large
sample size for each disorder. Furthermore, we used disorder-specific
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F IGURE 1 Predicted change from baseline for antidepressant- and placebo-treated participants with (a) generalized anxiety disorder, (b) social
anxiety disorder, (c) obsessive-compulsive disorder, and (d) PTSD. Predictions are derived from the full model, including nonsignificant interaction
terms. Data points were jittered to reduce over-plotting
primary outcomes and made full use of the longitudinal data by
employingmixedmodels.
Our study is limited by the limitations of the included trials. In
particular, minimum severity criteria restricted the number of partic-
ipants at the low end of the severity range. Half of the GAD trials
specified a minimum HAM-A score of 20, for instance, even though
most primary care patients with GAD have scores below 20 (Rollman
et al., 2005). Patients with comorbid disorders such as MDD were
also frequently excluded, even though thesedisorders commonlyoccur
together (Kessler, Chiu, Demler, &Walters, 2005).
Furthermore, our findings for PD are difficult to compare to the
other disorders. The best-fitting model showed that the ratio of the
number of panic attacks at endpoint in the placebo group compared
to the drug group remained constant, but this means that the drug–
placebodifference increasedwith increasing severity.Wehaveempha-
sized the latter, because this measure is most comparable to the other
disorders, but other choices could be made. Additionally, while the
number of panic attacks is a clinically relevant outcome, it does not
include other important facets of PD (e.g., agoraphobia). However, our
sensitivity analyses examining the PDSS also indicated that antide-
pressant efficacy increasedwith increasing baseline severity.
We also did not receive data for four trials. Since three of these
trials were negative, we may have overestimated antidepressant effi-
cacy for GAD, SAD, and OCD, but it seems unlikely that this would
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TABLE 2 Predicted change on the Hamilton Anxiety Rating Scale (HAM-A) and antidepressant–placebo difference after 8 weeks of treatment
for GAD
Predicted Change (95%CI)
Baseline Score Sample Size1 Placebo Antidepressant
Drug-Placebo
Difference (95%CI) SMD
10 79 2.7 (1.7–3.7) 4.1 (3.2–5.0) 1.4 (0.4–2.5) 0.21
15 259 5.4 (4.6–6.2) 7.4 (6.8–8.1) 2.1 (1.3–2.9) 0.29
20 1388 8.1 (7.5–8.7) 10.8 (10.3–11.3) 2.7 (2.1–3.3) 0.35
25 998 10.8 (10.3–11.3) 14.2 (13.7–14.6) 3.3 (2.8–3.9) 0.39
30 442 13.5 (12.9–14.1) 17.5 (17.0–18.0) 4.0 (3.4–4.6) 0.45
35 187 16.2 (15.5–17.0) 20.9 (20.2–21.5) 4.6 (3.8–5.4) 0.43
40 48 18.9 (17.9–20.0) 24.2 (23.3–25.1) 5.3 (4.2–6.3) 0.43
45 10 21.7 (20.4–22.9) 27.6 (26.5–28.7) 5.9 (4.6–7.2) 0.48
Notes. 1Sample size indicates the number of participants with a baseline score in between the indicated score and the subsequent score (e.g., 10 includes
participants with baseline scores between 10 and 14 (inclusive)).
F IGURE 2 Predicted numbers of panic attacks/2 weeks at endpoint
for antidepressant- and placebo-treated participants with panic disor-
der. Predictions are derived from the full model, including nonsignif-
icant interaction terms. Data points were jittered to reduce over-
plotting
have affected our findings regarding initial severity. Negative trials will
probably show little evidence for differential efficacy, so it is not likely
that we would have found a significant interaction effect for SAD and
OCD if we had been able to include these trials. For GAD, the evidence
for an interaction was sufficiently strong that it probably would have
remained even if we had added an additional trial in which differential
efficacy was not apparent.
Finally, because we obtained our data through CSDR, we could
only include manufacturer-sponsored trials of duloxetine, paroxetine,
and fluoxetine. We used CSDR because it allowed us to obtain a
nearly complete set of manufacturer-sponsored trials for these drugs.
Other approaches (e.g., a comprehensive literature search followed by
requesting IPD from authors) would almost certainly have introduced
much more significant biases into our trial selection, because of
reporting bias (Roest et al., 2015) and refusal or inability to share
data. For example, a study that took this approach for MDD trials
only received data for six of 23 trials (Fournier et al., 2010). Since
other SSRIs and SNRIs have similar pharmacological effects, it seems
unlikely that the relationship between initial severity and antidepres-
sant efficacy would be different. However, future research should
examine other antidepressants and non-industry-sponsored trials.
4.3 Clinical implications
To understand the implications of these findings, it should be noted
that the clinical relevance of a treatment effect is context-specific,
depending on such factors as the expected sequelae of the disease,
the costs and drawbacks of the treatment, and the efficacy of alterna-
tive treatments (Kraemer et al., 2003).Without an agreed-upon cut-off
point for a clinically relevant effect, it is difficult to establish a threshold
below which antidepressant efficacy for GAD and PD is not clinically
meaningful. For GAD, the SMDs do suggest that the antidepressant–
placebo difference is relatively small for patientswith a baseline sever-
ity score of 15 or less. Even without a definite cutoff point, though, it is
clear that the risk-benefit ratio forGADandPDbecomes less favorable
as initial severity decreases. It is therefore imperative that clinicians
transparently discuss the expected benefits of antidepressants with
patients with mild to moderate symptoms, who constitute the major-
ity of patients in primary care (Rollman et al., 2005).
There was no evidence for a relationship between initial severity
and antidepressant efficacy for SAD, OCD, and PTSD. Nevertheless,
other factors, such as anticipated course, patient preferences, and the
acceptability and efficacy of alternative treatments, could still lead to
different prescribing decisions for mild versus severe disorders, even
in the absence of differential efficacy.
5 CONCLUSIONS
We found that antidepressants are equally effective across the sever-
ity range generally included in clinical trials for SAD, OCD, and PTSD.
For GAD and PD, however, the benefits of antidepressants over and
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TABLE 3 Predicted endpoint number of panic attacks/2 weeks and antidepressant–placebo difference after 10 weeks of treatment for panic
disorder
Predicted No. Panic Attacks / 2Weeks (95%CI)
Baseline Score Sample Size1 Placebo Antidepressant Drug–PlaceboDifference
2 636 0.38 (0.31–0.46) 0.15 (0.13–0.19) 0.23 (0.16–0.29)
4 396 0.44 (0.37–0.54) 0.18 (0.15–0.22) 0.26 (0.19–0.34)
6 258 0.52 (0.43–0.63) 0.21 (0.17–0.26) 0.31 (0.22–0.40)
8 175 0.61 (0.51–0.74) 0.25 (0.21–0.30) 0.36 (0.26–0.47)
10 240 0.72 (0.60–0.86) 0.29 (0.24–0.35) 0.43 (0.30–0.55)
15 123 1.07 (0.89–1.29) 0.43 (0.36–0.52) 0.64 (0.45–0.82)
20 133 1.59 (1.31–1.93) 0.65 (0.53–0.78) 0.95 (0.67–1.23)
30 58 3.54 (2.82–4.45) 1.44 (1.14–1.80) 2.10 (1.43–2.78)
40 44 7.86 (5.93–10.41) 3.19 (2.41–4.21) 4.67 (2.98–6.37)
60 37 38.76 (25.78–58.28) 15.72 (10.50–23.55) 23.04 (12.23–33.83)
Notes. 1Sample size indicates the number of participants with a baseline score in between the indicated score and the subsequent score (e.g., 2 includes
participants with baseline scores of 2 or 3) or themaximum score (99).
aboveplaceboare small at lowseverity, and the trade-off betweenben-
efits and risks may therefore be unfavorable for these patients.
CONFLICT OF INTEREST
All authors have declared that they have no conflict of interest.
ORCID
Ymkje Anna de Vries PhD http://orcid.org/0000-0003-4580-4873
REFERENCES
Ackerman, D. L., & Greenland, S. (2002). Multivariate meta-analysis of con-
trolleddrug studies forobsessive-compulsivedisorder. Journal of Clinical
Psychopharmacology, 22(3), 309–317.
Altman, D. G., & Royston, P. (2006). The cost of dichotomising continu-
ous variables. British Medical Journal, 332(7549), 1080–1080. https://
doi.org/10.1136/bmj.332.7549.1080
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D.
(2015). Efficacy of treatments for anxiety disorders: A meta-analysis.
International Clinical Psychopharmacology, 30(4), 183–192. https://doi.
org/10.1097/YIC.0000000000000078
Curtiss, J., Andrews, L., Davis, M., Smits, J., & Hofmann, S. G. (2017). A
meta-analysis of pharmacotherapy for social anxiety disorder: An
examination of efficacy, moderators, and mediators. Expert Opin-
ion on Pharmacotherapy, 18(3), 243–251. https://doi.org/10.1080/
14656566.2017.1285907
Davis, M. L., Smits, J. A., & Hofmann, S. G. (2014). Update on the efficacy
of pharmacotherapy for social anxiety disorder: A meta-analysis.
Expert Opinion on Pharmacotherapy, 15(16), 2281–2291. https://
doi.org/10.1517/14656566.2014.955472
de Vries, Y. A., de Jonge, P., van den Heuvel, E., Turner, E. H., & Roest,
A. M. (2016). Influence of baseline severity on antidepressant effi-
cacy for anxiety disorders: Meta-analysis and meta-regression. British
Journal of Psychiatry, 208(6), 515–521. https://doi.org/10.1192/bjp.
bp.115.173450
Fournier, J. C., Derubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J.
D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant drug effects and
depression severity. Journal of the American Medical Association, 303(1),
47–53.
Gibbons, R. D., Hur, K., Brown, C. H., Davis, J. M., & Mann, J. J. (2012).
Benefits from antidepressants: Synthesis of 6-week patient-level out-
comes from double-blind placebo-controlled randomized trials of flu-
oxetine and venlafaxine. Archives of General Psychiatry, 69(6), 572–579.
https://doi.org/10.1001/archgenpsychiatry.2011.2044
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence,
severity, and comorbidity of 12-monthDSM-IVdisorders in the national
comorbidity survey replication. Archives of General Psychiatry, 62, 617–
627.
Khan, A., Bhat, A., Faucett, J., Kolts, R. L., & Brown, W. A. (2011).
Antidepressant-placebo differences in 16 clinical trials over 10 years at
a single site: Role of baseline severity.Psychopharmacology,214(4), 961–
965. https://doi.org/10.1007/s00213-010-2107-1
Khan, A., Brodhead, A. E., Kolts, R. L., & Brown, W. A. (2005). Severity of
depressive symptoms and response to antidepressants and placebo in
antidepressant trials. Journal of Psychiatric Research, 39(2), 145–150.
https://doi.org/10.1016/j.jpsychires.2004.06.005
Khan, A., Leventhal, R. M., Khan, S. R. F., & Brown, W. A. (2002). Severity of
depression and response to antidepressants and placebo: An analysis
of the Food and Drug Administration database. Journal of Clinical Psy-
chopharmacology, 22(1), 40–45.
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T.
J., & Johnson, B. T. (2008). Initial severity and antidepressant bene-
fits: A meta-analysis of data submitted to the food and drug admin-
istration. PLoS Medicine, 5(2), e45. https://doi.org/10.1371/journal.
pmed.0050045
Kraemer, H., Morgan, G. A., Leech, N., Gliner, J. A., Vaske, J. J., & Harmon,
R. J. (2003). Measures of clinical significance. The American Academy
of Child and Adolescent Psychiatry, 42(12), 1524–1529. https://doi.
org/10.1097/01.chi.0000091507.46853.d1
Krueger, R. F. (1999). The structure of common mental disorders.
Archives of General Psychiatry, 56(10), 921–926. https://doi.org/
10.1001/archpsyc.56.10.921
Montgomery, S. A. (1998). Implications of the severity of social phobia. Jour-
nal of Affective Disorders, 50 (Suppl 1), S17–S22.
Montgomery, S. A., McIntyre, A., Osterheider, M., Sarteschi, P., Zitterl, W.,
Zohar, J., … Wood, A. J. (1993). A double-blind, placebo-controlled
studyof fluoxetine inpatientswithDSM-III-Robsessive-compulsivedis-
order. The Lilly EuropeanOCDStudyGroup.EuropeanNeuropsychophar-
macology, 3(2), 143–152.
522 DEVRIES ET AL.
Montgomery, S. A., Sheehan, D. V., Meoni, P., Haudiquet, V., & Hackett, D.
(2002). Characterization of the longitudinal course of improvement in
generalized anxiety disorder during long-term treatmentwith venlafax-
ine XR. Journal of Psychiatric Research, 36(4), 209–217. Retrieved from
https://doi.org/S0022395602000055
National Institute for Health and Care Excellence. (2009). Depression in
adults: The treatment andmanagement of depression in adults (CG90), Lon-
don: Author.
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B.,
Soegaard, J., … Manniche, P. M. (1995). Paroxetine in the treat-
ment of panic disorder. A randomised, double-blind, placebo-controlled
study. British Journal of Psychiatry, 167, 374–379. https://doi.org/
10.1192/bjp.167.3.374
Pae, C.-U., Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S.,
& Serretti, A. (2015). Vortioxetine, a multimodal antidepressant for
generalized anxiety disorder: A systematic review and meta-analysis.
Journal of Psychiatric Research, 64, 88–98. https://doi.org/10.1016/
j.jpsychires.2015.02.017
Pollack,M.H.,Meoni, P.,Otto,M.W., Simon,N., &Hackett,D. (2003). Predic-
tors of outcome following venlafaxine extended-release treatment of
DSM-IV generalized anxiety disorder: A pooled analysis of short- and
long-term studies. Journal of Clinical Psychopharmacology, 23(3), 250–
259. https://doi.org/10.1097/01.jcp.0000084025.22282.84
Qaseem, A., Barry, M. J., & Kansagara, D. (2016). Nonpharmacologic ver-
sus pharmacologic treatment of adult patients with major depressive
disorder: A clinical practice guideline from the American College of
Physicians. Annals of Internal Medicine, 164, 350–359. https://doi.org/
10.7326/M15-2570
Rabinowitz, J., Werbeloff, N., Mandel, F. S., Menard, F., Marangell, L., &
Kapur, S. (2016). Initial depression severity and response to antide-
pressants v. placebo: Patient-level data analysis from 34 randomised
controlled trials. The British Journal of Psychiatry, 209(5), 427–428.
https://doi.org/10.1192/bjp.bp.115.173906
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A.,
& Turner, E. H. (2015). Reporting bias in clinical trials investigating the
efficacy of second-generation antidepressants in the treatment of anxi-
ety disorders: A report of 2meta-analyses. JAMAPsychiatry,72(5), 500–
510. https://doi.org/10.1001/jamapsychiatry.2015.15
Rollman, B. L., Belnap, B. H., Mazumdar, S., Zhu, F., Kroenke, K., Schul-
berg, H. C., & Katherine Shear, M. (2005). Symptomatic severity of
PRIME-MD diagnosed episodes of panic and generalized anxiety disor-
der in primary care. Journal of General Internal Medicine, 20(7), 623–628.
https://doi.org/10.1111/j.1525-1497.2005.0120.x
Shear,M.K., Brown,T.A., Barlow,D.H.,Money,R., Sholomskas,D. E.,Woods,
S. W., … Papp, L. A. (1997). Multicenter collaborative panic disorder
severity scale. American Journal of Psychiatry, 154, 1571–1575.
Soomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008).
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for
obsessive compulsive disorder (OCD). Cochrane Database of Systematic
Reviews, 1, CD001765.
Spijker, J., Bockting, C. L. H., Meeuwissen, J. A. C., van Vliet, I. M.,
Emmelkamp, P. M. G., Hermens, M. L. M., & van Balkom, A. J. L. M.
(2013).Multidisciplinaire richtlijn depressie (3e revisie), Utrecht: Trimbos-
instituut.
Stein, D. J., Ipser, J. C., & Seedat, S. (2006). Pharmacotherapy for post trau-
matic stress disorder (PTSD). Cochrane Database of Systematic Reviews,
1, CD002795.
Stein, D. J., Kasper, S., Andersen, E. W., Nil, R., & Lader, M. (2004). Escitalo-
pram in the treatment of social anxiety disorder: Analysis of efficacy for
different clinical subgroups and symptom dimensions. Depression and
Anxiety, 20(4), 175–181. https://doi.org/10.1002/da.20043
Stein, D. J., Stein, M. B., Goodwin, W., Kumar, R., & Hunter, B. (2001). The
selective serotonin reuptake inhibitor paroxetine is effective in more
generalized and in less generalized social anxiety disorder. Psychophar-
macology, 158(3), 267–272. https://doi.org/10.1007/s002130100880
Sugarman, M. A., Loree, A. M., Baltes, B. B., Grekin, E. R., & Kirsch, I. (2014).
The efficacy of paroxetine and placebo in treating anxiety and depres-
sion: Ameta-analysis of change on theHamilton rating scales. PLoSOne,
9(8), e106337. https://doi.org/10.1371/journal.pone.0106337
Thompson, S. G., & Higgins, J. P. T. (2002). How should meta-regression
analyses be undertaken and interpreted? Statistics in Medicine, 21(11),
1559–1573. https://doi.org/10.1002/sim.1187
Wong, J., Motulsky, A., Eguale, T., Buckeridge, D. L., Abrahamowicz, M.,
& Tamblyn, R. (2016). Treatment indications for antidepressants pre-
scribed in primary care in Quebec, Canada, 2006–2015. Journal of the
AmericanMedical Association, 315(20), 2230–2231.
SUPPORTING INFORMATION
Additional Supporting Informationmay be found online in the support-
ing information tab for this article.
How to cite this article: de Vries YA, Roest AM, Burgerhof
JGM, de Jonge P. Initial severity and antidepressant effi-
cacy for anxiety disorders, obsessive-compulsive disorder,
and posttraumatic stress disorder: an individual patient
data meta-analysis. Depress Anxiety. 2018;35:515–522.
https://doi.org/10.1002/da.22737
